ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

开始日期2020-07-01

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04314934

/ Completed临床2/3期

Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04575259

/ Completed临床2期

Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

100 项与 Blarcamesine 相关的临床结果

登录后查看更多信息

100 项与 Blarcamesine 相关的转化医学

登录后查看更多信息

100 项与 Blarcamesine 相关的专利（医药）

登录后查看更多信息

项与 Blarcamesine 相关的文献（医药）

2025-10-01·NEUROSCIENCE LETTERS

Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer’s disease model

Article

作者: Maurice, Tangui

Alzheimer's disease (AD) is the most common dementia, with rising global prevalence, still incomplete pathogenetic understanding and very limited effective therapies. Recent advances in biomarker identification of Aβ peptides and phospho-tau protein, and in anti-Aβ immunotherapy are suggesting that more early intervention will be more effective. Alternative therapeutic strategies to anti-Aß immunotherapy have received comparably less attention, yet one specific approach toward upstream neuroprotection by improvement of intracellular calcium homeostasis, activation of endogenous neuroprotection and restoration of autophagy through sigma-1 receptor activation recently demonstrated positive clinical data with oral blarcamesine in a phase IIb/III trial in 508 patients with early AD. AD-preventive approaches beyond lifestyle interventions become attractive candidates when meeting criteria of: (i) record of effective early intervention in mild disease, (ii) record of human safety, (iii) ease of administration, (iv) scalability to population level, (v) relative cost-effectiveness considering longer-term preventive use at population level. Here, we assessed blarcamesine's efficacy at preventing memory impairment and brain oxidative injury in the mouse preclinical model induced by intracerebroventricular injection of aggregated Aβ_25-35 peptide, that permitted a clean preventive approach before administration of the pathology-inducing amyloidogenic Aβ fragment. We observed significant preventions of Aβ_25-35-induced memory impairments, for both spatial working and contextual long-term memories, and of Aβ_25-35-induced increase in lipid peroxidation in the mouse hippocampi. These new insights, together with blarcamesine's clinical record in early AD render blarcamesine an attractive candidate for AD pharmacological prevention.

2025-05-01·JPAD-Journal of Prevention of Alzheimers Disease

Concerns about Anavex's clinical trial of Blarcamesine

Letter

作者: Brodkin, Jesse

2025-04-01·British journal of clinical pharmacology

The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome

Review

作者: Ette, Ene I. ; Fadiran, Emmanuel O. ; Missling, Christopher ; Hammond, Edward

Big data in drug development may not satisfactorily address the demands of precision medicine in a rare disease population, making the use of smaller clinical trials necessary. Consequently, the use of innovative design and analysis of these clinical trials using model‐informed approaches have become indispensable. This requires informative exposure–outcome analysis, together with formal statistical analysis, which should include the strength of evidence for a study outcome. We demonstrate how knowledge can be gained, with supporting strength of evidence, from a small (data) clinical trial with a low dose of blarcamesine in the treatment of Rett syndrome. Based on a small data paradigm, pharmacometrics item response theory modelling and Bayes factor analysis were used to demonstrate the efficacy of blarcamesine in Rett syndrome.

146

项与 Blarcamesine 相关的新闻（医药）

2025-11-28

·GlobeNewswire-Health Care

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Nov. 26, 2025 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held in San Diego, California from December 1-4, 2025. Presentation #1 (LB11) Title: Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 2, 4:35 pm PT – 4:50 pm PT Presentation #2 (P076) Title: Oral Blarcamesine Comparison to Normal Cognitive Aging: Demonstrating Alignment with Prodromal Cognitive Aging Trajectories in Precision Medicine Patient Population Phase IIb/III Trial – for Early Alzheimer’s Disease Patients Presenter: Audrey Gabelle, MD, PhD, Professor of Neurology, Neurologist and Member of the Anavex Scientific Advisory Board and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT Presentation #3 (P084) Title: Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT “We are excited to present, backed up by published clinical data, oral, once daily blarcamesine with its upstream mechanism of action restoring autophagy - the key driver in restoring cellular homeostasis, which could be essential to treating Alzheimer’s by activating the brain’s recycling process, which is impaired in Alzheimer’s disease. Blarcamesine demonstrated in early Alzheimer’s disease patients clinically meaningful effects of slowing cognitive decline with an adequate safety profile (no ARIA) as demonstrated in the Phase IIb/III program,” said Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board. “Additionally, our steadfast focus is on driving progress in Alzheimer’s disease development and providing meaningful options to improve the lives of patients and those who care for them.” This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers, CTAD’s mission is to create a platform that prioritizes substantive, clinical research-focused dialogue and collaboration. By fostering an intimate and collegial environment, CTAD has gained a reputation for facilitating impactful international collaborations and advancing the global AD research agenda. The upcoming 18th annual Clinical Trials on Alzheimer's Disease Conference (CTAD25) to be held in San Diego, CA (USA) on December 1-4, 2025. CTAD25 will build on the momentum of previous years, reflecting the rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today. CTAD25 also features thought-provoking roundtables and symposia that explore the latest advancements in AD research. Renowned clinicians and leaders from academia, research centers, patient coalitions, and pharmaceutical companies engage in dynamic discussions on diverse topics, from disease-modifying agents to gene therapy, vaccines, and multimodal interventions. The CTAD scientific program is underpinned by a rigorous peer-review abstract selection process, ensuring the presentation of high-quality research that drives the field forward. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. The content above comes from the network. if any infringement, please contact us to modify.

临床研究

2025-11-26

·anavex.com

One Oral Late Breaking Communication and Two Poster Presentation

One Oral Late Breaking Communication and Two Poster Presentations NEW YORK – November 26, 2025 Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held in San Diego, California from December 1-4, 2025. Details: Presentation #1 (LB11) Title: Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 2, 4:35 pm PT – 4:50 pm PT Title: Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 2, 4:35 pm PT – 4:50 pm PT Presentation #2 (P076) Title: Oral Blarcamesine Comparison to Normal Cognitive Aging: Demonstrating Alignment with Prodromal Cognitive Aging Trajectories in Precision Medicine Patient Population Phase IIb/III Trial – for Early Alzheimer’s Disease Patients Presenter: Audrey Gabelle, MD, PhD, Professor of Neurology, Neurologist and Member of the Anavex Scientific Advisory Board and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT Title: Oral Blarcamesine Comparison to Normal Cognitive Aging: Demonstrating Alignment with Prodromal Cognitive Aging Trajectories in Precision Medicine Patient Population Phase IIb/III Trial – for Early Alzheimer’s Disease Patients Presenter: Audrey Gabelle, MD, PhD, Professor of Neurology, Neurologist and Member of the Anavex Scientific Advisory Board and Doctor in Neurosciences at the Memory Resources Research Center, the Rare and Early Dementia Reference Center and the European Neurodegenerative Excellence Center of Montpellier University Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT Presentation#3 (P084) Title: Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT Title: Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine Presenter: Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board Time: December 1, 3:00 pm PT – December 2, 5:30 pm PT “We are excited to present, backed up by published clinical data, oral, once daily blarcamesine with its upstream mechanism of action restoring autophagy - the key driver in restoring cellular homeostasis, which could be essential to treating Alzheimer’s by activating the brain’s recycling process, which is impaired in Alzheimer’s disease. Blarcamesine demonstrated in early Alzheimer’s disease patients clinically meaningful effects of slowing cognitive decline with an adequate safety profile (no ARIA) as demonstrated in the Phase IIb/III program,” said Marwan Noel Sabbagh, MD, Professor of Neurology, and Chairman of the Anavex Scientific Advisory Board. “Additionally, our steadfast focus is on driving progress in Alzheimer’s disease development and providing meaningful options to improve the lives of patients and those who care for them.” This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About The 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers, CTAD’s mission is to create a platform that prioritizes substantive, clinical research-focused dialogue and collaboration. By fostering an intimate and collegial environment, CTAD has gained a reputation for facilitating impactful international collaborations and advancing the global AD research agenda. The upcoming 18th annual Clinical Trials on Alzheimer's Disease Conference (CTAD25) to be held in San Diego, CA (USA) on December 1-4, 2025. CTAD25 will build on the momentum of previous years, reflecting the rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today. CTAD25 also features thought-provoking roundtables and symposia that explore the latest advancements in AD research. Renowned clinicians and leaders from academia, research centers, patient coalitions, and pharmaceutical companies engage in dynamic discussions on diverse topics, from disease-modifying agents to gene therapy, vaccines, and multimodal interventions. The CTAD scientific program is underpinned by a rigorous peer-review abstract selection process, ensuring the presentation of high-quality research that drives the field forward. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Andrew J. Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com

临床2期临床3期

2025-11-23

·钟书神经药研所

MJFF：报告2025年帕金森病研发管线八大创新方向

点击上方蓝字关注“钟书神经药研所” 迈克尔·J·福克斯帕金森病研究基金会（MJFF）是全球领先的帕金森病研究组织，其使命是加速开发下一代帕金森病（PD）疗法，并最终寻求治愈方法。在一份《帕金森病重点治疗临床研发管线报告》中，来自MJFF的临床研发人员全面概述了当前帕金森病治疗领域的研发动态。 2025帕金森病整体研发管线概览自20世纪50-60年代左旋多巴及其他主要靶向多巴胺疗法获批上市以来，工业界不断推出日益多样化的治疗手段。许多疗法仍聚焦于多巴胺能系统，以解决疾病晚期核心的运动障碍。部分疗法则靶向其他脑内神经递质系统，有望改善帕金森病的非运动症状及其他并发症。深部脑刺激（DBS）和聚焦超声消融等外科神经调控技术的进展，也为应对运动挑战提供了更多选择。然而，目前尚无已获批疗法证实能够延缓或阻止帕金森病的病理进程及其导致的进行性残疾，这仍是当前治疗研发管线的关键目标。该份报告共追踪了截至2025年4月178种处于临床开发阶段的帕金森病疗法。其中疾病修饰疗法占主导（约占51%），该类疗法旨在延缓或阻止疾病进展。其次为针对PD患者运动症状管理的疗法，占34%；针对非运动症状与并发症管理的疗法占15%。目前处于临床阶段的疗法针对了多种广泛的PD病理生理学相关通路，反映了对PD复杂病理理解的深化。主要靶点包括： α-突触核蛋白 LRRK2 GBA1 炎症/免疫系统线粒体与代谢应激多巴胺及其他神经递质系统细胞替代疗法在研疗法中，小分子药物仍是主流（66%），但给药方式不断创新（例如采用皮下泵形式进行给药）；新型疗法如细胞疗法增长显著（12%），主要为多巴胺能细胞替代。生物制剂包括抗体/疫苗，约占6%，肽类（6%）、基因疗法（3%）和RNA靶向疗法（2%）等新型模式不断涌现。超过65%的临床阶段研发项目由商业公司主导，其中私营初创和新兴生物技术公司占比超过一半，显示出强大的早期创新能力。帕金森病八大创新疗法该报告重点跟踪了以下八大领域的创新疗法： 1. α-突触核蛋白靶向疗法 α-突触核蛋白的异常聚集是被认为是PD的核心病理标志物之一。目前在研的代表性产品包括：抗体类疗法：如罗氏的Prasinezumab（2025年6月宣布进入III期）、Bioarctic的Exidavnemab（II期）、Lundbeck的Amlenetug（针对多系统萎缩[MSA]，III期）。主动免疫疗法（疫苗）：如Vaxxinity的UB-312（I/II期）、AC Immune的ACI-7104（II期）。降低蛋白水平的其他疗法：如礼来的siRNA药物LY-3962681（减少α-syn产生，I期）、Annovis的Buntanetap（抑制α-syn聚集，III期），Allyx的ALX-001（I期，靶向mGluR5，可抑制α-syn毒性作用）。 2. LRRK2靶向疗法 LRRK2基因突变是常见的遗传性PD风险因素，其激酶活性过高与疾病相关。目前在研的代表性产品包括：小分子激酶抑制剂：如Denali/Biogen的DNL151（BIIB122，已进入II/III期研究阶段）、Neuron23的NEU-411（II期）。蛋白质降解剂：如Arvinas的ARV-102（I期），可标记并清除LRRK2蛋白。 RNA靶向疗法：如Ionis的ION-859（BIIB-094，ASO，I期，但Biogen已停止开发）。 3. GBA1靶向疗法 GBA1基因突变导致葡萄糖脑苷脂酶功能受损，是PD的重要风险因素。目前在研的代表性产品包括：小分子GCase增强剂：如Gain Therapeutics的GT-02287（I/II期）、Vanqua Bio的VQ-101（I期）。基因疗法：如Prevail/Lilly的PR-001（II期），旨在增加功能性GCase的表达。药物再利用（老药新用）：如 Ambroxol（多个II/III期试验），初步显示可增强GCase活性。 4. 神经免疫靶向疗法神经炎症在PD发病机制中起关键作用，通过抑制神经系统炎症可能对延缓PD疾病进展有帮助。目前在研的代表性产品包括： NLRP3炎症小体抑制剂：NLRP3是近期研发热点之一，如Ventyx的VTX-3232（II期）、Ventus的VENT-02（II期）。其他免疫调节抑制剂：如Biohaven的TYK2/JAK1抑制剂BHV-8000（进入II/III期）、GM-CSF（Sargramostim等，I期）、抗Galectin-3抗体TB-006（II期）。药物再利用（老药新用）：如Montelukast（II期，从哮喘药物 repurpose）。 5. 其他疾病生物学靶点疗法 GLP-1受体激动剂：多项临床研究正在进行中，但研究结果不尽一致。利司那肽（Lixisenatide）II期研究显示潜力，但艾塞那肽（Exenatide）III期研究未达主要终点。新型双靶点激动剂（如KP-405，GLP-1/GIP）也正在I期临床试验中。靶向线粒体与能量代谢：如Mission Therapeutics的USP30抑制剂MTX-325（I期，增强线粒体自噬）、Terazosin（II期，激活PGK1改善细胞能量）。 c-Abl抑制剂：如Risvodetinib（II期，可能由新公司继续开发），但Vodobatinib等因疗效不足已停止开发。靶向微生物组疗法：粪便微生物移植在多个II期试验中显示出对运动症状的轻度改善潜力。 6. 通用神经保护疗法神经保护疗法旨在增强神经细胞对病理损伤的抵抗力，而非直接靶向特定病理蛋白。目前在研的代表性产品包括：神经营养因子疗法：如Bayer/AskBio的GDNF基因疗法AB-1005（AAV2-GDNF，II期）、Herantis的CDNF模拟物HER-096（I期）。细胞疗法：多种间充质干细胞（MSCs）疗法在研，旨在通过分泌因子提供保护（I/II期）。其他神经保护疗法包括Nurr1激动剂ATH-399A（I期）、RXR激动剂IRX-4204（I期）等。 7.细胞替代疗法旨在通过移植多巴胺能前体细胞，替代PD患者中丢失的多巴胺神经元。近期多个早期临床试验（I/II期）报道了移植细胞的安全性和存活证据，以及初步的运动功能改善信号。主要包括：异体移植细胞疗法：使用胚胎干细胞或诱导多能干细胞系，如BlueRock的Bemdaneprocel（hESC来源，准备进入III期）、京都大学/Sumitomo的iPSC来源细胞（II期）。自体移植细胞疗法：使用患者自身的iPSC，避免免疫排斥，如Aspen Neuroscience的ANPD001（II期）。 8. 靶向神经递质小分子疗法通过影响和调节脑内神经递质水平，从而改善PD患者的运动和非运动症状。目前在研的代表性疗法包括：针对多巴胺能疗法的优化：如新型高选择性分子或长效/缓释制剂（如AbbVie的Tavapadon，III期）、皮下输注系统（如已批准的Vyalev、Onapgo，在研的ND0612）。非多巴胺能症状治疗：旨在改善PD认知障碍的疗法，如Anavex的Blarcamesine（II期，靶向Sigma-1受体）。改善PD姿势步态障碍，如IRLAB的Pirepemat（II期，靶向5-HT/去甲肾上腺素）、Atomoxetine（II期）。改善异动症，如Celon Pharma的PDE10A抑制剂CPL500036（II期）、Neurolixis的5-HT1A激动剂Befiradol（II期）。改善抑郁/焦虑，如Psilocybin（裸盖菇素，II期）。基因疗法，如MeiraGTx的AAV-GAD（II期，增强GABA能信号，改善运动症状）。更多阅读： IRLAB宣布两篇研究摘要将在2026年AD/PD大会发表，专注帕金森病创新药物研发【MDS 2025】非受体Abl激酶抑制剂Risvodetinib在早期帕金森病患者临床研究中显示希望帕金森病运动波动：MDS循证医学综述更新，8种治疗方案获“有效”推荐主要参考资料：Parkinson’s Disease Priority Therapeutic Clinical Pipeline Report ,Spring 2025 ,The Michael J. Fox Foundation for Parkinson’s Research. 声明：本文图片和内容主要来自官方和新闻网站，以及公开发表的学术会议或文献信息，如涉及版权问题，请联系删除。本文内容仅供信息分享和学术探讨之用，不构成任何形式的医学建议或健康指导。文｜神经小迷妹医学科普药学资讯长按关注

临床3期疫苗免疫疗法siRNA引进/卖出

100 项与 Blarcamesine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11383	Blarcamesine	-	DB05592

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	申请上市	欧盟	Anavex Life Sciences Corp.	2023-11-20
Rett综合征	临床3期	澳大利亚	Anavex Life Sciences Corp.	2019-05-06
Rett综合征	临床3期	英国	Anavex Life Sciences Corp.	2019-05-06
脆性X综合征	临床3期	美国	Anavex Life Sciences Corp.	-
帕金森病所致痴呆	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病所致痴呆	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床2期	西班牙	Anavex Life Sciences Corp.	2018-07-09
天使综合征	临床1期	-	Anavex Life Sciences Corp.	-
婴儿痉挛	临床1期	-	Anavex Life Sciences Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine (the early-start treatment groups)	鑰衊廠遞鑰齋淵艱製網(憲糧遞製繭餘衊淵廠憲): Difference (LS Mean) = -3.83, P-Value = 0.0165 更多	积极	2025-07-31
				Blarcamesine (the late-start treatment groups)
NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	blarcamesine (early start treatment)	蓋窪淵襯繭醖範淵顧醖(醖鏇獵窪鹽憲夢襯夢鹽) = from previously 25.2% in the ANAVEX®2-73-AD-004 trial to 9.6% in the ATTENTION-AD trial. 衊網構製鑰憲網繭鏇遞 (淵鏇獵壓艱鹹鏇夢製鏇 ) 更多	积极	2025-01-13
				blarcamesine (late start treatment)
NCT04314934 (GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine 50 mg	糧壓遞積繭夢鹹築糧鬱(艱選簾製鑰鹹壓獵蓋蓋) = 蓋製簾窪鬱網選憲鏇鑰鏇餘範願顧鏇壓夢鏇鑰 (獵夢顧顧鹹窪憲餘鏇積 ) 更多	积极	2024-07-28
				Blarcamesine 30 mg	糧壓遞積繭夢鹹築糧鬱(艱選簾製鑰鹹壓獵蓋蓋) = 憲夢觸蓋壓積壓齋觸顧鏇餘範願顧鏇壓夢鏇鑰 (獵夢顧顧鹹窪憲餘鏇積 ) 更多
NCT04304482 (EXCELLENCE, GlobeNewswire) 人工标引	临床2/3期	Rett综合征	92	ANAVEX2-73	夢齋膚構餘醖鹹鬱夢壓(膚醖鏇衊範窪壓鏇鏇糧) = 簾遞鬱築網憲願餘膚廠鏇襯蓋鑰鹹壓觸鹽廠願 (鬱鹽齋齋鏇鬱鑰艱構淵, 2.150) 更多	积极	2024-01-02
				Placebo	夢齋膚構餘醖鹹鬱夢壓(膚醖鏇衊範窪壓鏇鏇糧) = 廠艱廠觸網選繭糧顧艱鏇襯蓋鑰鹹壓觸鹽廠願 (鬱鹽齋齋鏇鬱鑰艱構淵, 2.537) 更多
NCT03790709 (Corporate Publications) 人工标引	临床2/3期	阿尔茨海默症	508	ANAVEX2-73	壓獵齋糧餘網襯繭糧糧(衊願膚網顧壓蓋獵糧簾): Difference = -1.783 (95% CI, −3.314 ~ −0.251), P-Value = 0.0226 达到更多	积极	2023-09-14
				Placebo
NCT03790709 (ANAVEX2-73-AD-004, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	509	Blarcamesine	範鹹夢獵醖夢糧廠憲範(構醖鏇顧構齋淵夢醖積): OR = 1.84, P-Value = 0.015 更多	积极	2022-12-01
				Placebo
NCT03758924 (Biospace) 人工标引	临床2期	Rett综合征 SIGMAR1	-	Blarcamesine	觸憲願憲襯築遞觸醖夢(觸積鏇鹹壓觸蓋夢製蓋) = 糧獵餘鹹衊壓鑰夢壓膚遞獵鬱構鬱窪夢艱範選 (蓋築鏇憲膚鑰糧艱餘窪 ) 更多	积极	2021-06-21
				Placebo	-
CTAD2015	临床2期	-	-	ANAVEX 2-73	襯窪鑰觸範製築壓廠餘(夢遞製鹹膚艱鬱衊廠窪) = The average Cogstate test improved across the test batteries 網鹽鑰壓願醖範構醖築 (獵獵願鬱顧積蓋艱衊淵 ) 更多	积极	2015-11-04